Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer.
Metachronous tumors
Second lung cancer
Stereotactic ablative radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
07 Jun 2023
07 Jun 2023
Historique:
received:
31
07
2022
accepted:
20
05
2023
medline:
9
6
2023
pubmed:
8
6
2023
entrez:
7
6
2023
Statut:
epublish
Résumé
Early-stage lung cancer, primarily treated with surgery, often occur in poor surgical candidates (impaired respiratory function, prior thoracic surgery, severe comorbidities). Stereotactic ablative radiotherapy (SABR) is a non-invasive alternative that provides comparable local control. This technique is particularly relevant for surgically resectable metachronous lung cancer, in patients unable to undergo surgery.. The objective of this study is to evaluate the clinical outcome of patients treated with SABR for stage I metachronous lung cancer (MLC) versus stage I primary lung cancer (PLC). 137 patients treated with SABR for stage I non-small cell lung cancer were retrospectively reviewed, of which 28 (20.4%) were MLC and 109 (79.6%) were PLC. Cohorts were evaluated for differences in overall survival (OS), progression-free survival (PFS), metastasis-free survival, local control (LC), and toxicity. After SABR, patients treated for MLC have comparable median age (76.6 vs 78.6, p = 0.2), 3-year LC (83.6% vs. 72.6%, p = 0.2), PFS (68.7% vs. 50.9%, p = 0.9), and OS (78.6% vs. 52.1%, p = 0.9) as PLC, along with similar rates of total (54.1% vs. 42.9%, p = 0.6) and grade 3 + toxicity (3.7% vs. 3.6%, p = 0.9). Previous treatment of MLC patients was either surgery (21/28, 75%) or SABR (7/28, 25%). The median follow-up was 53 months. SABR is a safe and effective approach for localized metachronous lung cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Early-stage lung cancer, primarily treated with surgery, often occur in poor surgical candidates (impaired respiratory function, prior thoracic surgery, severe comorbidities). Stereotactic ablative radiotherapy (SABR) is a non-invasive alternative that provides comparable local control. This technique is particularly relevant for surgically resectable metachronous lung cancer, in patients unable to undergo surgery.. The objective of this study is to evaluate the clinical outcome of patients treated with SABR for stage I metachronous lung cancer (MLC) versus stage I primary lung cancer (PLC).
PATIENTS AND METHODS
METHODS
137 patients treated with SABR for stage I non-small cell lung cancer were retrospectively reviewed, of which 28 (20.4%) were MLC and 109 (79.6%) were PLC. Cohorts were evaluated for differences in overall survival (OS), progression-free survival (PFS), metastasis-free survival, local control (LC), and toxicity.
RESULTS
RESULTS
After SABR, patients treated for MLC have comparable median age (76.6 vs 78.6, p = 0.2), 3-year LC (83.6% vs. 72.6%, p = 0.2), PFS (68.7% vs. 50.9%, p = 0.9), and OS (78.6% vs. 52.1%, p = 0.9) as PLC, along with similar rates of total (54.1% vs. 42.9%, p = 0.6) and grade 3 + toxicity (3.7% vs. 3.6%, p = 0.9). Previous treatment of MLC patients was either surgery (21/28, 75%) or SABR (7/28, 25%). The median follow-up was 53 months.
CONCLUSION
CONCLUSIONS
SABR is a safe and effective approach for localized metachronous lung cancer.
Identifiants
pubmed: 37287020
doi: 10.1186/s13014-023-02286-5
pii: 10.1186/s13014-023-02286-5
pmc: PMC10249156
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97Informations de copyright
© 2023. The Author(s).
Références
Pract Radiat Oncol. 2017 Sep - Oct;7(5):295-301
pubmed: 28596092
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):261-269
pubmed: 32044413
Eur J Surg Oncol. 2021 Jul;47(7):1791-1796
pubmed: 33468371
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Radiother Oncol. 2013 Jun;107(3):403-8
pubmed: 23746675
Anticancer Res. 2015 May;35(5):3103-7
pubmed: 25964602
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1378-1390
pubmed: 27479723
Front Oncol. 2014 Jun 25;4:151
pubmed: 25009800
J Med Imaging Radiat Oncol. 2012 Oct;56(5):561-6
pubmed: 23043577
CA Cancer J Clin. 2017 Mar;67(2):138-155
pubmed: 28140453
J Thorac Cardiovasc Surg. 1975 Oct;70(4):606-12
pubmed: 170482
Radiother Oncol. 2013 Oct;109(1):1-7
pubmed: 24128806
J Clin Oncol. 2017 Jan 20;35(3):268-270
pubmed: 27937087
J Thorac Oncol. 2021 Jul;16(7):1166-1175
pubmed: 33845213
Cancer Manag Res. 2020 Oct 20;12:10361-10374
pubmed: 33116891
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lung Cancer. 2014 Jul;85(1):7-11
pubmed: 24768582
Chest. 2007 Sep;132(3 Suppl):1S-19S
pubmed: 17873156
Clin Lung Cancer. 2015 Sep;16(5):e91-6
pubmed: 25659504
Cancer. 2013 Sep 15;119(18):3402-10
pubmed: 23798353
Int J Hyperthermia. 2018 Dec;34(8):1329-1336
pubmed: 29378462
J Thorac Oncol. 2015 Aug;10(8):1195-200
pubmed: 26200274
Clin Lung Cancer. 2019 Mar;20(2):107-116
pubmed: 30477740
Transl Oncol. 2017 Jun;10(3):442-449
pubmed: 28448960
J Int Med Res. 2013 Dec;41(6):1779-87
pubmed: 24265329
Radiother Oncol. 2012 Jul;104(1):19-22
pubmed: 22248508
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
BMC Surg. 2019 Dec 3;19(1):185
pubmed: 31795997
J Thorac Dis. 2019 Mar;11(Suppl 4):S523-S536
pubmed: 31032071
Thorax. 2004 Jul;59(7):602-7
pubmed: 15223870
Lung Cancer. 2015 Mar;87(3):303-10
pubmed: 25617985
Ann Thorac Surg. 1995 Apr;59(4):863-6; discussion 867
pubmed: 7695410
Radiat Oncol. 2015 Feb 18;10:43
pubmed: 25889747
PLoS One. 2018 Dec 17;13(12):e0209002
pubmed: 30557376